V. Roussel‐Robert

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Thierry Calvez, Hérvè Chambost, Ségolène Claeyssens‐Donadel et al. · Blood · 2014 · 151 citations · Full text

Medicine, Hematology, Pediatrics +15

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

Annie Borel‐Derlon, Augusto B. Federici, V. Roussel‐Robert et al. · Journal of Thrombosis and Haemostasis · 2007 · 123 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +11

Continuous infusion of B‐domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience

Natalie Stieltjes, Carmen Altisent, Günter Auerswald et al. · Haemophilia · 2004 · 35 citations

Medicine, Hematology, Surgery +17

Impact of Choice of Treatment for Bleeding Episodes on Inhibitor Outcome in Patients With Mild/Moderate Hemophilia A and Inhibitors

Roseline d’Oiron, Fabienne Volot, J. Reynaud et al. · Seminars in Hematology · 2006 · 24 citations

Medicine, Hematology, Pharmacotherapy +15

Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus

Natalie Stieltjes, N. Ounnoughène, Emilie Sava et al. · British Journal of Haematology · 2004 · 24 citations

Medicine, Infectious Diseases, Pathology +15